ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc. (ZVSA) dilution facts from SEC filings
Snapshot as of Mar 31, 2026, built from 28 SEC filings.
- Warrants outstanding
- 10 warrant series recorded as outstanding
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.